Aurobindo Unit 7 gets USFDA observations

Hyderabad-based Aurobindo Pharma Limited today said two of its manufacturing facilities, Unit 3 and Unit 7 underwent pre-approval inspection by US Food and Drug Administration.

In a reply to stock exchanges over a related news report, the company stated that there were no Form 483 observations issued for Unit 3 but there were some for the latter.

"With regard to Unit 7 there were certain observations," Aurobindo said. "The company is appropriately responding and this has no perceived impact on the operations and exports from the said facility". A spokesperson, when contacted. stated that these units underwent inspection by the US FDA last week.